Atossa Genetics Inc. (YAG2.F)

1.1140 -0.0300 (-2.62%) At close: 08:06AM CEST

Atossa Genetics Inc.

107 Spring Street
Seattle, WA 98104
United States
206 588 0256
https://www.atossatherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 12

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Steven C. Quay FCAP, M.D., Ph.D.	Chairman, CEO & President	1.13M	N/A	1951
Ms. Heather Rees CPA	Senior VP of Finance & Principal Accounting Officer	485.63k	N/A	1973
Ms. Delly Behen P.H.R.	Senior Vice President of Administration & HR	N/A	N/A	N/A
Mr. Eric Van Zanten	Vice President of Investor & Public Relations	N/A	N/A	N/A
Dr. Richard Graydon M.D., Ph.D.	Interim Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Corporate governance

Atossa Genetics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.